Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/16/2017 10/17/2017 10/18/2017 10/19/2017 10/20/2017 Date
121.885(c) 118.7(c) 117.55(c) 115.63(c) 114.4457 Last
1 041 238 1 049 566 1 044 789 1 220 434 692 682 Volume
-0.91% -2.61% -0.97% -1.63% -1.02% Change
More quotes
Financials ($)
Sales 2017 78,6 M
EBIT 2017 -470 M
Net income 2017 -465 M
Finance 2017 467 M
Yield 2017 -
Sales 2018 125 M
EBIT 2018 -495 M
Net income 2018 -485 M
Finance 2018 265 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 129x
EV / Sales2018 82,8x
Capitalization 10 607 M
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics.It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined... 
More about the company
Surperformance© ratings of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALNYLAM PHARMACEUTICALS, I
01:01p ALNYLAM PHARMACEUTICALS : and Collaborators to Present APOLLO Phase 3 Study Resu..
10:17a ALNYLAM PHARMACEUTICALS : and Vir Form Strategic Alliance to Advance RNAi Therap..
10/19 ALNYLAM PHARMACEUTICALS : Researchers from Alnylam Pharmaceuticals, Inc. Discuss..
10/19 ALNYLAM PHARMACEUTICALS : heads higher as it strikes US$1bn-plus licencing deal ..
10/19 ALNYLAM PHARMACEUTICALS : Stealthy Vir allies with Alnylam and others to build i..
10/18 ALNYLAM PHARMACEUTICALS : and Vir Form Strategic Alliance to Advance RNAi Therap..
10/05 ALNYLAM PHARMACEUTICALS : Initiates Phase 2 Clinical Study of Cemdisiran ALN-CC5..
09/28 HERE ARE TWO PHASE II TRIALS TO WATC : Alnylam Pharmaceuticals, Inc. (NASDAQ:ALN..
09/28 ALNYLAM PHARMACEUTICALS : Initiates Phase 2 Clinical Study of Cemdisiran in Pati..
09/27 ALNYLAM PHARMACEUTICALS : Continues Leadership in RNAi Technologies and Delivery..
More news
Sector news : Biotechnology & Medical Research - NEC
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
10/18DJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
10/19Head-To-Head Comparison: AC Immune SA $ACIU vs. Alnylam Pharmaceuticals $ALN.. 
10/18#3-- Going for it: George Scangos gets more than $500M, sets up pipeline deal..
4
10/18Alnylam teams up with Vir Biotech to advance RNAi therapeutics to treat infec.. 
10/18$ALNY (+1.1% pre) Stealthy Vir allies with Alnylam and others to build infect.. 
10/1820 Stocks Moving In Wednesday's PreMarket
8
More tweets
Qtime:122
News from SeekingAlpha
10/19 BIOTECH DEVELOPER STOCKS : What Are The Best Wealth-Builders Now?
10/18 Alnylam teams up with Vir Biotech to advance RNAi therapeutics to treat infec..
10/17 The Medicines Company May Not Be The Best Investment In 2017
10/17 BIOTECH ANALYSIS CENTRAL : Daily Pharma News - October 17, 2017
10/10 An In-Depth Look At Alexion's Competition And Upcoming Catalysts
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Technical analysis trends ALNYLAM PHARMACEUTICALS, I
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 117 $
Spread / Average Target 1,2%
EPS Revisions
Managers
NameTitle
John M. Maraganore Chief Executive Officer & Director
Barry E. Greene President
Michael W. Bonney Chairman
Yvonne L. Greenstreet Chief Operating Officer & Executive Vice President
Manmeet Singh Soni Chief Financial Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ALNYLAM PHARMACEUTICALS, INC.208.84%10 783
INCYTE CORPORATION13.96%24 254
QUINTILES IMS HOLDINGS INC33.89%21 711
CELLTRION, INC.--.--%20 802
LONZA GROUP59.15%19 730
SEATTLE GENETICS, INC.21.30%9 108